

Hande H Tuncer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1657356/publications.pdf>

Version: 2024-02-01

15
papers

370
citations

1478505

6
h-index

1199594

12
g-index

15
all docs

15
docs citations

15
times ranked

685
citing authors

#	ARTICLE	IF	CITATIONS
1	<p><p>The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy</p>. Blood and Lymphatic Cancer: Targets and Therapy, 2020, Volume 10, 1-5.</p>	2.7	1
2	Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia. Haematologica, 2020, 106, 284-287.	3.5	8
3	Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice. Clinical Cancer Research, 2019, 25, 4264-4270.	7.0	61
4	A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL. Blood Advances, 2019, 3, 1568-1573.	5.2	26
5	A Case of Primary Refractory Immune Thrombocytopenia: Challenges in Choice of Therapies. Case Reports in Hematology, 2018, 2018, 1-4.	0.4	2
6	Outcomes of frontâ€line ibrutinib treated CLL patients excluded from landmark clinical trial. American Journal of Hematology, 2018, 93, 1394-1401.	4.1	52
7	Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. Haematologica, 2018, 103, 1511-1517.	3.5	135
8	Venetoclax As Monotherapy or in Combination: Patterns of Use and Predictors of Outcomes in an International Multicenter Study of CLL Patients. Blood, 2018, 132, 3142-3142.	1.4	2
9	Racial, age, and sex disparities in chronic lymphocytic leukemia (CLL) patients treated with novel therapies.. Journal of Clinical Oncology, 2018, 36, 6577-6577.	1.6	0
10	Mind It: Increasing Rate of Mental Health Disorders in Hospitalized Sickle Cell Patients. Blood, 2018, 132, 4689-4689.	1.4	1
11	Adverse Events, Patterns of Tumor Lysis Syndrome Prophylaxis and Management, and Dosing Patterns in a Large Cohort of Venetoclax Treated CLL Patients in Community and Academic Settings. Blood, 2018, 132, 4410-4410.	1.4	0
12	Treatment Patterns and Outcomes of Patients with CLL Treated with Chemoimmuno- and Novel Agent-Based Therapy: A Multicenter Study. Blood, 2018, 132, 4759-4759.	1.4	1
13	Propensity Score Matched Analysis of Risk for Malignancies in Sickle Cell Anemia. Blood, 2018, 132, 5885-5885.	1.4	0
14	Umbilical Cord Mesenchymal Stem Cells Increase Expansion of Cord Blood Natural Killer Cells. Biology of Blood and Marrow Transplantation, 2008, 14, 1031-1038.	2.0	80
15	Ex-Vivo Expansion and mRNA Transfection of Cord Blood Derived Natural Killer Cells with Preserved Cytotoxicity.. Blood, 2006, 108, 3659-3659.	1.4	1